Reinhard Kandera
Net Worth
Last updated:
What is Reinhard Kandera net worth?
The estimated net worth of Dr. Reinhard Kandera is at least $1,159,302 as of 21 Aug 2023. He owns shares worth $35,142 as insider and has received compensation worth at least $1,124,160 in HOOKIPA Pharma Inc..
What is the salary of Reinhard Kandera?
Dr. Reinhard Kandera salary is $562,080 per year as Chief Financial Officer & Director in HOOKIPA Pharma Inc..
How old is Reinhard Kandera?
Dr. Reinhard Kandera is 56 years old, born in 1969.
What stocks does Reinhard Kandera currently own?
As insider, Dr. Reinhard Kandera owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| HOOKIPA Pharma Inc. (HOOK) | Chief Financial Officer & Director | 43,092 | $0.82 | $35,142 |
What does HOOKIPA Pharma Inc. do?
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Reinhard Kandera insider trading
HOOKIPA Pharma key executives
HOOKIPA Pharma Inc. executives and other stock owners filed with the SEC:
- Dr. Igor Matushansky M.D., Ph.D. (52) Chief Medical Officer and Global Head of R&D
- Dr. Reinhard Kandera (56) Chief Financial Officer & Director
- Mr. Joern Aldag (66) Chief Executive Officer & Director